SCHEMBL14148598

SCHEMBL14148598

Nc1sc(-c2ccc(Cl)cc2)nc1-c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.57
PTGDR2 Q9Y5Y4 5/20 0.57
ALDH1A1 P00352 4/20 0.57
HPGD P15428 3/20 0.57
CYP1A2 P05177 2/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
LMNA P02545 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
GAA P10253 2/20 0.51
APEX1 P27695 1/20 0.49
MEN1 O00255 3/20 0.48
MAPT P10636 3/20 0.48
KMT2A Q03164 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
GBA1 P04062 1/20 0.47
MAPK1 P28482 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
DPP4 P27487 1/20 0.47
MGAM O43451 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL543631 0.89 ALDH1A1 (0.50) KDM4EPTGDR2ALDH1A1HPGDCYP1A2
SCHEMBL14148599 0.85 ADORA1 (0.53) KDM4EPTGDR2ALDH1A1HPGDCYP1A2
SCHEMBL14148613 0.84 ADORA2A (0.55) KDM4EPTGDR2ALDH1A1HPGDCYP1A2
SCHEMBL14148757 0.83 PTGDR2 (0.57) KDM4EPTGDR2ALDH1A1CYP1A2CYP2C19
SCHEMBL11652829 0.83 ALOX5 (0.54) KDM4EPTGDR2ALDH1A1LMNAGAA
SCHEMBL544858 0.81 CDC7 (0.61) KDM4EPTGDR2ALDH1A1HPGDCYP1A2
SCHEMBL11462189 0.81 KDM4E (0.58) KDM4EPTGDR2ALDH1A1HPGDCYP1A2
SCHEMBL11460695 0.81 KDM4E (0.58) KDM4EPTGDR2ALDH1A1HPGDCYP1A2
SCHEMBL11284205 0.81 KDM4E (0.58) KDM4EPTGDR2ALDH1A1HPGDCYP1A2
SCHEMBL11456645 0.80 APEX1 (0.72) KDM4EPTGDR2ALDH1A1HPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008090382-A1 THIAZOLE AND OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PRION DISEASES, CANCER AND CONDITIONS OF THE CENTRAL NERVOUS SYSTEM AS WELL AS IN THE REGULATION OF STEM CELLS THE UNIVERSITY OF SHEFFIELD (GB) 2008-07-31 WO disclosed